GKOS has a dominant MIGS franchise, a corneal health business growing 40%+, and a just-launched product that could redefine keratoconus care. At $103 — 31% below the 52-week high and 31% below consensus — the pullback is pricing in failure that the fundamentals don't support.
GKOS printed 41% YoY revenue growth in Q1 2026, raised 2026 guidance, and just launched Epioxa — the first FDA-approved topical keratoconus therapy, now with a permanent J-code in hand. The stock is trading 31% below analyst consensus and 30% below its 52-week high. At $103, you're buying the dip before Epioxa's reimbursement ramp shows up in the numbers.
Full thesis
Glaukos is an ophthalmic medtech/pharma hybrid with two durable franchises: a dominant position in minimally invasive glaucoma surgery (MIGS) via the iStent and Hydrus product lines, and a corneal health franchise anchored by corneal cross-linking and the newly launched Epioxa. Revenue has compounded from $283M in 2022 to $507M in 2025 — a 21% CAGR — with Q1 2026 accelerating to 41% YoY growth. The stock is down 30% from its 52-week high on a non-cash Q4 charge and general medtech multiple compression. At $103 vs a $149 consensus target, the market is pricing in meaningful execution risk that the operating results simply do not support. The Epioxa launch — first FDA-approved topical keratoconus therapy with a permanent CMS J-code in hand — is the under-appreciated catalyst.
Glaukos: Before Epioxa Gets Priced In
GKOS has a dominant position in minimally invasive glaucoma surgery, a corneal health business growing 40%+, and a just-launched product that could redefine keratoconus care. The stock has given back six months of gains on a noisy non-cash charge and macro noise. At $103 — 31% below the 52-week high and 31% below analyst consensus — running the math on whether the market is right to be skeptical.
The Bottom Line
Three things determine where GKOS goes from here: does Epioxa reimbursement ramp faster than the market expects, does the iStent/Hydrus franchise maintain its mid-teens volume growth, and does management demonstrate a credible path to profitability in 2027. Get the first one right and the bull case is obvious. Miss on profitability timing and the story becomes a grind. The current price is not giving Glaukos credit for any of it.
Where We've Been
GKOS spent much of early 2025 in no-man's land — growing well but with the overhang of a large convertible note balance and a Street that hadn't fully modeled the Epioxa opportunity. Then a series of catalysts drove the stock from $73 to $148. Then one bad quarter — driven by a non-cash accounting charge, not operational deterioration — gave most of it back.
GKOS share price · Jan 2025 → Jun 2026
The catalysts that mattered
| Date | Catalyst | Stock Reaction |
|---|---|---|
| Mar 2025 | Q4 2024 earnings: Revenue $383M (+22% FY), both segments accelerating. Street upgrades begin. iStent volume gaining share in MIGS market as ASC adoption expands. | +9% on the week |
| May 2025 | Q1 2025: $107M revenue, +24% YoY. Corneal health international expansion starting to show up in numbers. FDA advisory committee signals receptive view on Epioxa ahead of approval. | +8% on the print |
| Aug 2025 | Q2 2025: $124M revenue, +28% YoY. Management raises FY2025 guidance. Convertible note balance reduced via equity offering. Balance sheet risk perceived to be clearing. | +11% on the day |
| Oct 2025 | Q3 2025: $134M revenue, +31% YoY — acceleration in both segments. International corneal health franchise growing faster than domestic. Stock touches 52-week high near $148. | +7% on earnings |
| Feb 23, 2026 | Q4 2025 and FY2025 results: $507M full-year revenue (+32% YoY), but Q4 included ~$113M non-cash charge on convertible note extinguishment. GAAP net loss looked catastrophic at -$134M in one quarter. Market focused on the headline, not the footnote. | −14.7% over two weeks |
| Mar 19, 2026 | Epioxa commercial launch announced. First FDA-approved topical keratoconus therapy. No UV equipment required at treatment. New workflow significantly broadens addressable provider base. | +4% on the day |
| Apr 15, 2026 | CMS assigns permanent J-code for Epioxa. This is the reimbursement unlock — outpatient facilities can now bill directly without temporary codes. Dramatically simplifies ASC and clinic adoption. | +5% on the news |
| Apr 29, 2026 | Q1 2026 blowout: $150.6M revenue, +41% YoY. Non-GAAP EPS -$0.18 vs est. -$0.30 — a 40% beat. Both segments at records. Guidance raised. Stock popped, then drifted lower with macro noise. | +8% on day; faded since |
| Jun 2, 2026 | Stock at $103, testing 200-day MA of $105.77. Presenting at William Blair Growth Stock Conference today. 31% below Street consensus of $149. | Near 200-day support |
The Q4 2025 "catastrophe" that knocked GKOS from $140 to $120 was a non-cash loss on the extinguishment of legacy convertible notes — an accounting event tied to the settlement of debt that had been on the balance sheet since the 2022 Ivantis acquisition. The long-term debt balance went from $283M at end of 2023 to near zero by end of 2024, largely converted to equity. Glaukos took the associated accounting charge in Q4 2025. The underlying business — revenue, gross margin, cash burn — was unaffected. Market participants who saw -$134M net income in a single quarter and sold without reading the footnotes gave a gift to anyone who looked deeper.
Q1 2026: The Print the Market Ignored
Revenue of $150.6M on 41% year-over-year growth. Non-GAAP EPS -$0.18 against a consensus of -$0.30 — a 40% beat. Both the glaucoma and corneal health segments at record levels. 2026 guidance raised. The stock bounced 8%, then gave it back. That mismatch between operating performance and stock behavior is the opportunity.
Segment breakdown
| Segment | Q1 2026 | YoY |
|---|---|---|
| Glaucoma | ~$87M | ~+35% |
| Corneal Health | ~$64M | ~+50% |
| Total Revenue | $150.6M | +41% |
| Gross Profit | $117.2M | +42% |
| Gross Margin | 77.9% | vs 77.2% Q1'25 |
| Operating Loss | ($19.9M) | vs ($20.7M) Q1'25 |
| Non-GAAP EPS | ($0.18) | vs est. ($0.30) |
Segment split estimated from company reporting patterns and management commentary. Corneal health includes first contribution from Epioxa (commercial launch March 19).
What management said
CEO Tom Burns noted that the Q1 result reflected "record performances in both our glaucoma and corneal health segments," and that the company had "a strong start to what we believe will be a transformative year for Glaukos."
On Epioxa: management described early clinical feedback as "exceptional," with eye care professionals citing the simplified workflow and elimination of the UV riboflavin preparation step as a major differentiator. The permanent J-code secured in April was described as "the final piece needed for broad ASC adoption."
Revised FY2026 guidance: revenue raised to approximately $620–640M, ahead of prior guidance and consensus. That implies 22–26% growth for the full year after a 41% Q1 — meaning the back half is modeled conservatively.
Operating loss trajectory: management guided to continued operating leverage through 2026, with the path to cash flow breakeven now framed as a 2027 objective rather than a longer-term aspiration.
The World's Smallest Implant, in the World's Largest Eye Disease
Glaucoma affects approximately 80 million people worldwide and is the leading cause of irreversible blindness. Glaukos invented the MIGS category — minimally invasive glaucoma surgery — with the original iStent in 2012. A decade later, the company owns the two leading MIGS devices globally and the category is still in early innings.
The iStent franchise
The iStent inject W is a trabecular micro-bypass stent — roughly the size of a grain of sand — implanted during routine cataract surgery to reduce intraocular pressure without a separate surgical procedure. It requires no additional OR time beyond the cataract case. For the roughly 4 million annual cataract surgery patients in the US who also have glaucoma, it's a concurrent procedure that can reduce or eliminate their need for lifelong eye drops (which cost $2,000–$5,000 per year and have poor adherence rates).
The 2022 acquisition of Ivantis — maker of the Hydrus Microstent — for $475M added the second major MIGS device to the portfolio. Hydrus uses a scaffold design that opens a 90-degree arc of the trabecular meshwork vs. iStent's two bypass channels. Different mechanisms, different patient populations, same sales force. The acquisition doubled Glaukos's glaucoma portfolio breadth and eliminated its only serious MIGS competitor in a single transaction.
Why the runway is long
The global cataract surgery market sees approximately 25 million procedures per year, with roughly 30–40% of patients having clinically significant glaucoma or elevated IOP that could benefit from concurrent MIGS. Current MIGS adoption across that eligible population is estimated at 20–25%. If penetration doubles over the next decade — a reasonable outcome given an aging global population, growing glaucoma awareness, and expanding reimbursement coverage internationally — that's a multi-year volume tailwind for Glaukos regardless of pricing dynamics.
Key market dynamics that favor continued penetration:
- Eye drop compliance is terrible. Published studies show only 50–60% adherence to glaucoma medication regimens. When a cataract surgeon can reduce drop burden in 3 minutes at no incremental risk to the patient, the clinical argument is straightforward.
- ASC (ambulatory surgery center) expansion. Cataract surgery has migrated rapidly from hospital ORs to lower-cost ASCs. ASCs have stronger economic incentives to adopt add-on procedures that increase revenue per case without adding time. MIGS fits this model precisely.
- International expansion underway. Glaukos has approvals and growing commercial infrastructure in Europe, Japan, and emerging markets. MIGS penetration outside the US is materially lower, representing a multi-year international volume ramp.
- The Hydrus data. The HORIZON trial showed Hydrus patients had significantly lower IOP and less medication use than cataract surgery alone at 5 years. Long-duration clinical data builds surgeon confidence and informs coverage decisions. More data, more adoption.
Pricing and reimbursement
MIGS devices are reimbursed under CMS CPT codes 0191T (iStent) and 0449T (Hydrus), with average per-procedure reimbursement of approximately $800–$1,100 in the hospital outpatient and ASC settings. Private payer coverage has expanded substantially since 2020. International reimbursement is less uniform but improving — Japan's NHI approval process for Hydrus completed in 2024, opening a major new market. The ASP (average selling price) Glaukos realizes is not disclosed at the segment level but is believed to be in the $800–$1,000 range per unit, with consistent market leadership sustaining pricing power.
Epioxa: A New Product Hitting a Neglected Market
Keratoconus is a progressive corneal disease affecting roughly 1 in 2,000 people — approximately 500,000 to 1 million patients in the US. It causes the cornea to thin and bulge outward, progressively distorting vision. Left untreated, it leads to corneal transplant. Current treatment is corneal cross-linking (CXL), a procedure using UV light and riboflavin drops to strengthen corneal collagen. Glaukos has dominated this market since acquiring the Photrexa franchise in 2019. Epioxa changes the economics of the procedure entirely.
The existing Photrexa franchise
Glaukos's Photrexa and Photrexa Viscous are the only FDA-approved riboflavin drugs for corneal cross-linking in the US. The procedure requires a UV light device (which Glaukos also sells/leases), the drug, and a trained ophthalmologist. It's a meaningful workflow — typically a 60-90 minute session with a prior epithelial debridement step.
The Photrexa franchise has been growing steadily. The market remains massively underpenetrated: only 50,000–60,000 CXL procedures are performed annually in the US against an estimated 1 million+ eligible patients. The bottleneck has been the requirement for specialized equipment, the procedure time, and historically incomplete reimbursement.
Epioxa: the game-changer
Epioxa is Glaukos's next-generation corneal cross-linking drug — a topical formulation that does not require the epithelial removal step of standard CXL. This is clinically significant for two reasons: it reduces procedure time, and it eliminates a step that limits the number of providers willing to perform the procedure.
But the bigger commercial story is the workflow simplification. Traditional CXL requires a UV light device. Epioxa, as a topical pharmaceutical, can potentially be administered in a broader range of outpatient settings. For the large segment of ophthalmology practices that want to treat keratoconus but haven't invested in UV equipment, Epioxa opens a new channel.
On April 15, 2026 — three weeks after commercial launch — CMS assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code to Epioxa. This is not a minor administrative detail. A permanent J-code means: outpatient facilities can bill for Epioxa as a separately reimbursable pharmaceutical using a standardized code recognized by all payers. Before the J-code, facilities had to use temporary or miscellaneous codes that required pre-authorization, case-by-case processing, and significant billing overhead. The J-code removes the single biggest adoption friction in the outpatient setting. It typically takes 6-18 months for a new drug to receive a permanent J-code — Glaukos got it in 3 weeks. That reflects CMS's recognition of Epioxa as meeting a clear unmet clinical need.
Market size math
If Epioxa can expand the treated keratoconus population from 50,000–60,000 annual procedures to 150,000+ over 5 years — a fraction of the eligible patient pool — and if average revenue per treatment is $1,800–$2,200 (consistent with the pharmaceutical pricing structure), the Epioxa opportunity alone could add $150–$200M in incremental annual revenue on top of the existing Photrexa base. That's a meaningful step-up for a company currently running at $640M in total annual revenue.
The bear case on Epioxa is reimbursement friction from private payers, who are slower to adopt than Medicare. The permanent J-code addresses government payer billing. Commercial payer coverage decisions take 12–24 months to fully cascade through networks. That lag creates the window where the stock underprices the opportunity — the launch has happened, the J-code is in hand, but the revenue ramp won't fully show for 3–6 more quarters.
Retinal disease: the long option
Glaukos has early-stage programs in retinal diseases, including a partnership with Lux Biosciences for sustained-release drug delivery to the back of the eye. These are not in the near-term financial model. They represent optionality — a pipeline with real clinical foundation but no near-term revenue contribution. The market isn't paying for them, which is appropriate. But they add to the long-arc thesis that Glaukos is building toward being the dominant platform for ophthalmic disease beyond glaucoma and corneal disorders.
Revenue Trajectory & The Path to Profitability
GKOS has compounded revenue at 21% annually since 2022. The gross margin structure — consistently above 75% and expanding — supports the eventual profitability case. The operating losses are shrinking. The question is timing: at what revenue level does GKOS cross into consistent profitability, and how far away are we?
GKOS revenue by segment · 2022A → 2028E
Gross margin vs. operating loss · 2022A → 2027E
| Year | Revenue | YoY | Gross Margin | Op. Loss | Notes |
|---|---|---|---|---|---|
| FY 2022A | $283M | −4% | 75.6% | ($82M) | Ivantis acquisition close; integration costs peak |
| FY 2023A | $315M | +11% | 76.0% | ($129M) | Ivantis integration; convertible debt on B/S; recovery begins |
| FY 2024A | $383M | +22% | 75.5% | ($122M) | Revenue acceleration; convertible debt converted/repaid |
| FY 2025A | $507M | +32% | 77.5% | ($87M) | Large non-cash charge in Q4 on note extinguishment |
| FY 2026E | ~$645M | ~+27% | ~78.5% | ~($60M) | Epioxa ramp begins; guidance raised; leverage improving |
| FY 2027E | ~$780M | ~+21% | ~79.5% | ~($15M) | Approaching operating breakeven; Epioxa volume growing |
| FY 2028E | ~$900M | ~+15% | ~80%+ | $40M+ | Operating profitability; potential for first GAAP net income |
Source: company filings, Q1 2026 earnings release and raised guidance, analyst estimates (consensus ~$645M FY2026). FY2027-28 estimates derived from consensus revenue growth rates and management commentary on operating leverage trajectory. EV/Revenue 2026E at current price: approximately 9.5x.
GKOS doesn't have positive GAAP earnings, so traditional P/E multiples are not the right tool. The relevant frameworks are EV/Revenue (current enterprise value divided by forward revenue) and EV/Gross Profit (which adjusts for the high gross margin business). At $103/share and ~$6.1B market cap, with approximately net neutral debt, EV/Revenue 2026E is roughly 9.5x. EV/Gross Profit 2026E is approximately 12x. For a medical device/pharma hybrid growing 27% with 78%+ gross margins and an identifiable path to profitability, comparables suggest 10–14x forward revenue is the appropriate range. The current price implies the low end of that range — pricing in meaningful execution risk.
SWOT
Where Glaukos wins, where it bleeds, where the upside lives, what to watch.
Strengths
- Category inventor and dominant MIGS player — iStent and Hydrus together own the MIGS market; no significant competitors have a credible near-term challenge to either device in the US
- 41% Q1 2026 revenue growth — not a one-quarter flash; the four-quarter trend is 24%, 28%, 31%, 41% — acceleration, not deceleration
- 77.9% gross margin — expanding, not compressing; mix shift to Epioxa pharmaceutical revenue will push this toward 80%
- Epioxa launched + permanent J-code secured — the two primary commercial prerequisites are in place; execution is now the variable
- Balance sheet deleveraged — legacy $283M convertible debt fully resolved; net debt now negligible (~$49M); financial risk materially lower than 2023
- High recurring revenue character — once cataract surgeons adopt iStent/Hydrus, they use it in essentially every eligible case; this is a recurring consumable dynamic with device-like economics
- Orphan Drug designation for Epioxa — provides 7 years of market exclusivity for keratoconus indication; no generic or biosimilar competition during the ramp period
Weaknesses
- Not yet profitable — operating losses of $87M in 2025; GAAP net losses will continue through at least 2026; requires patience and a growth-investor mindset
- High stock-based compensation — $63M in SBC in 2025 (12.4% of revenue) inflates the gap between GAAP and non-GAAP results; dilutes existing shareholders over time
- Epioxa adoption risk — commercial payer coverage decisions lag Medicare; the revenue ramp will be slower than bulls hope in 2026; initial quarters will disappoint relative to bull case assumptions
- Ivantis integration cost — the 2022 acquisition created $282M intangibles still amortizing; P&L will carry D&A headwind through 2026-2027
- Elective procedure exposure — MIGS and CXL are not emergency procedures; macro weakness that delays cataract surgery or elective ophthalmology visits directly reduces volume
- Small-cap liquidity — at $6B market cap, institutional position sizing creates volatility; retail/sentiment-driven moves can be extreme in either direction
Opportunities
- Epioxa commercial ramp — only 50,000–60,000 CXL procedures annually vs. 1M+ eligible patients; even a 2x increase in treated volume is 5–6 years of runway from today's base
- International expansion — MIGS penetration outside the US is significantly lower; Japan approval for Hydrus in 2024 opens the world's second-largest medical device market
- Operating leverage kicking in — R&D and SG&A as % of revenue should decline materially as revenue scales from $500M toward $900M+ without proportional cost growth
- Path to profitability re-rate — pre-profitability medtech companies re-rate meaningfully when GAAP profitability becomes visible; 2027 breakeven could trigger institutional buying from value managers who can't own money-losing companies
- Retinal disease pipeline — early-stage programs not in current model; sustained-release ophthalmic drug delivery has multi-billion dollar TAM; optionality not priced at $103
- Aging demographics — glaucoma and keratoconus incidence grows with age; the demographic tailwind is secular and multi-decade
- M&A target — Glaukos's ophthalmic platform, proprietary drug formulations, and MIGS devices make it an obvious acquisition target for larger medical device companies (Alcon, J&J MedTech, Bausch + Lomb) seeking ophthalmic growth
Threats
- Epioxa reimbursement timeline — private payer coverage decisions are slow; commercial payers could create 12–18 months of friction that delays the revenue ramp and tests investor patience
- Competitive entry in MIGS — iStar Medical's MIGS device (Belgium-based) has European approval; if it reaches US markets with a clinical differentiation story, it could pressure iStent share
- Macro/consumer sensitivity — 2026 macro uncertainty could delay elective cataract surgery, which is the primary vehicle for MIGS adoption; any material weakness in cataract procedure volumes hits Glaukos directly
- Multiple compression for pre-profitability names — rising interest rates or a growth-to-value rotation compresses EV/Revenue multiples even if the underlying business performs; GKOS has felt this dynamic in 2026
- Foreign exchange — international expansion means growing non-USD revenue; USD strength creates reported revenue headwinds on constant-currency growth
- Patent cliff (long-term) — Photrexa patents expire in the 2030s; Epioxa's Orphan Drug exclusivity runs 7 years from approval (2031+); timeline is long but noted
- SBC dilution creep — $63M in annual SBC on a ~59M share base (~1.5% annual dilution rate) is manageable but sustained; shareholders need revenue growth to outpace the dilution math
Bull · Base · Bear
Twelve-month forward scenarios. Probabilities anchored to current analyst dispersion ($135–$170 target range) and the two key binary questions: does Epioxa ramp materially faster than conservative guidance implies, and does management demonstrate a credible 2027 profitability path by year-end 2026?
$155
Epioxa exceeds expectations in H2 2026. Commercial payer coverage decisions come faster than expected, driven by the permanent J-code and patient advocacy. CXL procedure volume inflects toward 80,000–90,000 annual US cases by year-end. FY2026 revenue comes in at $660–680M, above guidance. Management provides credible 2027 profitability guide in Q3/Q4 earnings calls. The narrative shifts from "pre-profitability growth story" to "approaching profitability medtech platform" and attracts a new cohort of institutional buyers. EV/Revenue expands toward 12x 2027E revenue of ~$800M. Consensus upgrades to $170–180 range. Multiple: 12x 2027E Rev.
$130
Steady execution — Epioxa ramps gradually, glaucoma holds. FY2026 revenue hits guidance of $625–645M (+23–27%). Epioxa contributes meaningfully but commercial payer friction slows the pace; quarterly results don't dramatically beat or miss. Glaucoma franchise grows mid-to-high teens on volume and international expansion. Operating loss narrows to $50–65M. Management sets a 2027 path to operating breakeven or near it. Stock re-rates toward $130 as the discount to consensus narrows but doesn't close. This is roughly what the Street is pricing at $103 with a $149 target: gradual re-rating, no catalyst surprise required. Multiple: 10x 2026E Rev.
$75
Epioxa reimbursement disappoints; macro hits elective procedures. Commercial payers deny Epioxa coverage broadly or add step-therapy requirements that delay adoption by 18–24 months. Simultaneously, macro deterioration causes a 5–8% decline in elective cataract surgery volumes — reducing the primary MIGS insertion opportunity. Revenue growth slows to 15–17% in 2026, missing guidance. Cash burn becomes a concern; management raises equity to fund operations at dilutive prices. Multiple compresses to 7–8x forward revenue. Bear case is not an existential scenario — the franchise is real — but it takes the stock back to the $73–80 range last seen in early 2025 when the debt risk was more prominent. Floor is likely the prior base of $73. Multiple: 7x 2026E Rev.
Price scenarios · Jun 2026 → Jun 2027
Time-Horizon Outlook
What to watch across the next three months, the rest of 2026, 2027, and the longer arc.
Jun–Aug 2026
Stock is at 200-day support. Today's William Blair conference is an opportunity for management to re-engage institutional investors post-pullback.
- William Blair conference (Jun 2) — first major investor appearance since Q1 beat; watch for any Epioxa commentary
- Stifel Ophthalmology Forum (May 26, passed) — physician-facing data; useful for understanding clinical adoption sentiment
- Q2 2026 earnings (late July/early August) — $155–165M implied by guidance trajectory; beat vs. miss on Epioxa commentary will be the dominant stock driver
- Watch: commercial payer coverage decisions for Epioxa. Any announced payer contracts would be a significant positive catalyst.
- Risk: Q2 cataract surgery data from ASC networks could signal macro-related volume pressure in the glaucoma segment
Sep–Dec 2026
The Epioxa narrative becomes quantifiable. By Q3/Q4, investors will have 2–3 quarters of data to assess whether the ramp is tracking expectations.
- Q3 and Q4 Epioxa contribution will be the dominant narrative; even modest outperformance vs. conservative guidance could catalyze a re-rating
- Operating loss trajectory — if Q3 operating loss prints below $40M, profitability timeline becomes credible for 2027
- International MIGS volume: Japan, EU expansion update — could be a positive surprise that consensus isn't modeling fully
- FY2026 guide: any upward revision to the $620–640M range reinforces the bull case
- Risk: if commercial payers deny coverage broadly or add restrictive prior-authorization requirements for Epioxa, management will need to reset expectations
The profitability year
If consensus is right that Glaukos approaches operating breakeven in 2027, this is the year the investor base changes character — growth buyers already in, value buyers start entering.
- Operating breakeven or near-miss: the structural shift that unlocks institutional mandates that can't hold GAAP-loss companies
- Epioxa at scale: 80,000–100,000+ annual procedures if ramp tracks; meaningful revenue contribution becoming visible in run rate
- International expansion: second-wave MIGS volume from Japan and developing markets; incremental operating leverage from existing salesforce
- Pipeline optionality: retinal disease updates could provide next-leg narrative ahead of the 2028 timeframe
- Risk: if 2027 profitability is missed, stock faces another year of carrying cost for patient holders
The platform thesis
If the three product lines — iStent/Hydrus, Photrexa/Epioxa, retinal pipeline — all contribute meaningfully, Glaukos becomes something larger than a single-franchise medical device company.
- Revenue approaching $1B with positive operating income — transforms the valuation framework
- Orphan exclusivity for Epioxa intact through 2031+ — no competitive pressure on the highest-margin product line
- Potential M&A target: Alcon, J&J, Bausch + Lomb, or a large pharmaceutical company with ophthalmic ambitions would find GKOS's proprietary platform highly strategic at $6-8B enterprise value
- Free cash flow generation: once profitable, the high gross margin character of the business (78%+) should produce strong FCF conversion; share buybacks or further pipeline investment become options
- Tail risk: MIGS penetration plateau if glaucoma pharmaceutical options improve dramatically; retinal pipeline development failure
Risk Matrix
Ranked by what would actually move the stock 20%+ in either direction over the next twelve months.
Glossary
| Term | Definition |
|---|---|
| MIGS | Minimally Invasive Glaucoma Surgery. A category of glaucoma procedures typically performed concurrently with cataract surgery, using micro-scale devices to reduce intraocular pressure with significantly lower risk than traditional surgical approaches like trabeculectomy. Glaukos invented this category. |
| Keratoconus | A progressive eye disease where the cornea thins and bulges outward into a cone shape, distorting vision. Affects approximately 1 in 2,000 people. Without treatment, it can progress to the point requiring corneal transplant. Treated with corneal cross-linking (CXL) to halt progression. |
| CXL (Corneal Cross-Linking) | A procedure that uses UV light combined with riboflavin (vitamin B2) drops to strengthen the collagen bonds in the cornea, halting keratoconus progression. Glaukos's Photrexa is the only FDA-approved riboflavin for this procedure in the US. |
| J-Code | A Healthcare Common Procedure Coding System (HCPCS) code assigned by CMS to pharmaceutical and biologic products administered in outpatient settings. A permanent J-code allows facilities to bill for a drug as a separate line item, dramatically simplifying reimbursement and reducing administrative friction for adoption. |
| iStent inject W | Glaukos's second-generation trabecular micro-bypass stent — one of the world's smallest FDA-approved implantable medical devices. Implanted during cataract surgery in under 3 minutes, it creates two bypass channels through the trabecular meshwork to reduce intraocular pressure. |
| Hydrus Microstent | A crescent-shaped scaffold that dilates Schlemm's canal over a 90-degree arc, acquired by Glaukos via the 2022 Ivantis acquisition. Differs mechanistically from iStent; provides surgeons and patients a choice of MIGS approaches with different clinical profiles. |
| Epioxa | Glaukos's next-generation topical corneal cross-linking formulation, FDA-approved and commercially launched in March 2026. First topical keratoconus therapy to receive a permanent CMS J-code (April 2026). Simplifies the CXL workflow by eliminating the epithelial debridement step required in standard CXL. |
| IOP | Intraocular Pressure. The primary modifiable risk factor for glaucoma progression. MIGS devices reduce IOP by improving aqueous humor outflow through the trabecular meshwork. Target IOP reduction of 20–30% is typical for MIGS procedures. |
| ASC | Ambulatory Surgery Center. Outpatient surgical facility that handles same-day procedures. Cataract surgery has largely migrated from hospital ORs to ASCs, which have stronger economic incentives to adopt add-on procedures like MIGS that increase per-case revenue without proportionally increasing cost. |
| Orphan Drug Designation | FDA designation for drugs treating conditions affecting fewer than 200,000 patients in the US. Provides 7 years of market exclusivity, tax credits, and accelerated review. Glaukos's Epioxa holds Orphan Drug designation for keratoconus, providing protection through approximately 2031–2032. |